Inovio initiates early-stage clinical trials for cervical cancer drug
- Inovio is starting clinical trials of INO-3221 for the treatment of human papillomavirus (HPV)-associated cervical cancer.
- INO-3112 is a DNA immunotherapy product.
- The first study is an open-label trial that will assess safety, immunogenicity, clinical responses and disease-free survival.
The most recent statistics from the American Cancer Society (ACS) report that approximately 12,360 women in the US will be diagnosed with cervical cancer this year, and 4,020 women will die from it.
Inovo is conducting early-stage clinical trials to evaluate INO-3112, which is a combination of the company’s lead immunotherapy product, VGX-3100 and its immune activator expressing interleukin 12 (IL-12), in women with inoperable advanced cervical cancer. Primary endpoints include clinical responses at the tumor site and disease-free survival.
- Pharmaceutical Business Review Inovio begins Phase I/IIa cervical cancer trial of INO-3112